## Editor's Note Regarding "Mechanism of Corticotropin-Releasing Factor Type I Receptor Regulation by Nonpeptide Antagonists" In the above article [Hoare SR, Sullivan SK, Ling N, Crowe PD, and Grigoriac (2003) Mol Pharmacol 63:751–765], the authors used a compound, NBI 35965, for

In the above article [Hoare SR, Sullivan SK, Ling N, Crowe PD, and Grigoriadis DE (2003) *Mol Pharmacol* **63:**751–765], the authors used a compound, NBI 35965, for which the chemical name and structure were not provided at the time of the original publication. The authors have now made this structure available (below) for interested readers.

NBI 35965 [(S)-6-cyclopropylmethyl-2-(2,4-dichlorophenyl)-7-ethyl-4-methyl-7,8-dihydro-6H-1,3,6,8 $\alpha$ -tetraaza-acenaphthylene mesylate].

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 17, 2024